Aspreva Pharmaceuticals Corp. (ASPV) and Roche Holdings AG will not submit regulatory filings for using the drug CellCept to treat lupus nephritis because its Phase III trial showed the drug was not "superior" to another treatment.
The Victoria, B.C., pharmaceutical company Aspreva said the trial compared CellCelpt, an immunosuppresant, with intravenous cyclophosphamide to treat the disease, which causes swelling of the kidneys.
The disease is caused by a malfunction of the immune system, which, if suppressed, can relieve symptoms.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment